GRAZ, Austria, October 2 /PRNewswire/ -- ORIDIS Biomed, a biopharmaceutical company developing targeted treatment solutions for liver diseases, announced today that it has appointed Wolfgang Senne as Chief Financial Officer. Prior to joining ORIDIS Biomed Wolfgang Senne held various executive positions in the European and US life science industry, including Siemens Medical Solutions, Carl Zeiss Medical Systems, and GeneScan Europe AG. He takes over from acting CFO / COO Dr. Reinhold Bayer who retires.
"I am extremely pleased about the international experience and the operational expertise that Wolfgang is bringing to ORIDIS Biomed." said Peter Hecht, PhD, CEO of ORIDIS Biomed. "Wolfgang's background in commercialization and finances in research driven life science industries, specifically on the US market, will help us further extend our international presence."
"I want to thank Reinhold for the tremendous contributions he has made to the Company," said Hecht. "Reinhold's background in financial management and administration was instrumental in successfully developing our TISSOMICS(TM) research platform, and in initiating ORIDIS Biomed's drug development programs."
"ORIDIS Biomed has managed to successfully commercialize its TISSOMICS(TM) research platform, bringing medical relevance early into the drug development process," said Wolfgang Senne. "At the same time, ORIDIS Biomed has applied this platform to its own drug development programs, and I am most impressed by the potential of this approach."
Wolfgang Senne started his business life at the medical devices business of Siemens. During his career he held several executive positions in Europe and the USA, focusing on the development of new products and worldwide marketing within the life science area. In 2001, he joined GeneScan Europe AG, a biotech company focusing on microbiological analytical systems, where he held the positions of CFO, and CEO. Wolfgang Senne joins ORIDIS Biomed after holding interim executive manager position in a life science start-up. He will relocate to Graz, Austria from Germany with his family.
About TISSOMICS(TM)
TISSOMICS(TM) is a proprietary disease-driven research platform enabling the medical validation of drug discovery approaches and biomarkers. ORIDIS Biomed has a license from the Medical University of Graz, Austria for the commercial access to BioResource-Med biobank, one of the world's largest collections of diseased human tissues and associated medical data.
TISSOMICS(TM) has been successfully applied in co-operations and partnerships with leading pharmaceutical and biotechnology companies to deliver medical validation to their drug discovery or biomarker programs using optimized genomic and proteomic approaches.
About ORIDIS Biomed
ORIDIS Biomed is a biopharmaceutical company, developing therapeutics, diagnostics and biomarkers (targeted treatment solutions) for liver diseases. Therapeutic programs include primary liver cancer (hepatocellular carcinoma, HCC), and metabolic liver diseases, such as alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH), where incidence rates are rapidly increasing due to modern life-styles, while treatment options are limited, expensive, and often ineffective.
ORIDIS Biomed uses its proprietary TISSOMICS(TM) platform also in its own research and development programs. In addition, the Company commercializes the TISSOMICS(TM) research platform in collaborations with industrial partners.
ORIDIS Biomed is a privately held company, based in Graz, Austria.
For further information, please visit ORIDIS Biomed's website at www.oridis-biomed.com
ORIDIS Biomed Forschungs- und Entwicklungs GmbHCONTACT: Company Contact: Dr Peter Hecht, CEO, ORIDIS Biomed Forschungs-und Entwicklungs GmbH, +43-316-325776, info@oridis-biomed.com. MediaContact: Frank Butschbacher, IR/Communications, +43-650-7844940,office@butschbacher.net
